Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Drugs of Today

• Publication date

  2015-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1358/dot.2015.51.9.2368554PMID 26488032
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Long‐term treatment with empagliflozin as add‐on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus

  2015cited by this paper
• Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.

  2015cited by this paper
• Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition

  2015cited by this paper
• Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group Study

  2015cited by this paper
• Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors

  2015cited by this paper
• Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.

  2015cited by this paper
• Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16‐week, randomized, placebo‐controlled trial

  2015cited by this paper
• SGLT inhibition and euglycaemic diabetic ketoacidosis.

  2015cited by this paper
• Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet

  2015cited by this paper
• Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers

  2015cited by this paper
• Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program

  2015cited by this paper
• Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes

  2015cited by this paper
• The potential role of sodium glucose co‐transporter 2 inhibitors in the early treatment of type 2 diabetes mellitus

  2015cited by this paper
• Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin

  2015cited by this paper
• The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.

  2015cited by this paper
• 8. Cardiovascular Disease and Risk Management

  2014cited by this paper
• Luseogliflozin: First Global Approval

  2014cited by this paper
• Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

  2014cited by this paper
• Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

  2014cited by this paper
• Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes

  2014cited by this paper
• Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study

  2014cited by this paper
• Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

  2014cited by this paper
• Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in Japanese patients with type 2 diabetes mellitus.

  2014cited by this paper
• Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.

  2014cited by this paper
• Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus

  2014cited by this paper
• Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial

  2014cited by this paper
• Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial

  2014cited by this paper
• Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial

  2014cited by this paper
• Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

  2014cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2014cited by this paper
• Ipragliflozin: First Global Approval

  2014cited by this paper
• Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.

  2014cited by this paper
• Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment

  2014cited by this paper
• Effect of gemfibrozil, rifampicin, or probenecid on the pharmacokinetics of the SGLT2 inhibitor empagliflozin in healthy volunteers.

  2014cited by this paper
• Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and simvastatin following co-administration in healthy volunteers.

  2014cited by this paper
• Tofogliflozin: First Global Approval

  2014cited by this paper
• Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.

  2014cited by this paper
• Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment

  2014cited by this paper
• The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

  2014cited by this paper
• Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK

  2014cited by this paper
• Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus

  2013cited by this paper
• Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.

  2013cited by this paper
• Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia

  2013cited by this paper
• Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

  2013cited by this paper
• Effect of food on the pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and assessment of dose proportionality in healthy volunteers.

  2013cited by this paper
• Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects

  2013cited by this paper
• The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010

  2013cited by this paper
• A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers.

  2013cited by this paper
• Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

  2013cited by this paper
• Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

  2013cited by this paper
• Effect of Empagliflozin on the Steady-State Pharmacokinetics of Ethinylestradiol and Levonorgestrel in Healthy Female Volunteers

  2013cited by this paper
• Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin

  2013cited by this paper
• Lack of drug–drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers

  2013cited by this paper
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus

  2013cited by this paper
• Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans

  2013cited by this paper
• A Phase IIb, randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

  2013cited by this paper
• Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, and metformin following co-administration in healthy volunteers.

  2013cited by this paper
• Safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in healthy Japanese subjects.

  2013cited by this paper
• Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes

  2013cited by this paper
• Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

  2012cited by this paper
• The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

  2012cited by this paper
• Long‐term treatment with empagliflozin, a novel, potent and selective SGLT‐2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats

  2012cited by this paper
• Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?

  2012cited by this paper
• Pharmacokinetics of Empagliflozin, a Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor, Coadministered with Sitagliptin in Healthy Volunteers

  2012cited by this paper
• From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus.

  2009cited by this paper
• Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.

  2005cited by this paper
• Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies

  2005cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper

• Sodium–glucose cotransporter 2 inhibitor therapy reduces the administration frequency of steroid injection in patients with diabetic macular edema: A cohort study using the Japanese health insurance claims database

  2024cites this paper
• A sensitive ultra-performance liquid chromatography-tandem mass spectrometry method for the simultaneous quantification of assay and trace-level genotoxic tosylate analogs (methyl and ethyl) in empagliflozin and its tablet dosage forms.

  2023cites this paper
• Sodium-Glucose Co-Transporter 2 Inhibitors Reduce Macular Edema in Patients with Diabetes mellitus

  2022cites this paper
• Sodium-Glucose Cotransporter 2 Inhibitors Improve Chronic Diabetic Macular Edema

  2020cites this paper
• Managing diabetes and liver disease association.

  2018cites this paper
• Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus

  2017cites this paper
• Rosemary Extract as a Potential Anti-Hyperglycemic Agent: Current Evidence and Future Perspectives

  2017cites this paper
• Effect of Empagliflozin on Tacrolimus‐Induced Pancreas Islet Dysfunction and Renal Injury

  2017cites this paper